Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

Pfizer

₹5228.9 0.5 | 0%

Market Cap ₹23921 Cr.

Stock P/E 43.4

P/B 6.4

Current Price ₹5228.9

Book Value ₹ 819.9

Face Value 10

52W High ₹6452.9

Dividend Yield 0.67%

52W Low ₹ 4015.1

Pfizer Research see more...

Overview Inc. Year: 1950Industry: Pharmaceuticals & Drugs

Pfizer Ltd is an India-based pharmaceutical agency. The Company has a portfolio of approximately 150 products across over 15 therapeutic areas. The Company is engaged in production, advertising, buying and selling and exporting pharmaceutical products. The Company gives various merchandise for anti-diabetic, erectile disorder, gastrointestinal (GI), multivitamins, anti-infectives, cardiovascular, dermatology, neurology, ache/fever/infection and autoimmune problems, amongst others. Its merchandise consist of Viagra, Daxid, Tricorex, Mucaine, Diamox, Hetrazan, Enbrel, Ativan, Pacitane, Folvite Tablets, Autrin Capsules, Prevenar 13, Wysolone, Loette, anti-infectives, cardiovascular, dermatology, Trulimax, Vibazime DT, Ovral G, Ovral L, Premarin pills, Premarin Vaginal Cream, Zosyn, Wymox, Tygacil, Cynomycin, Targit, Cyklokapron and Magnamycin. The Company has its personal production facility at Thane and Goa. The Company has numerous impartial settlement/third party manufacturers based throughout the country.

Read More..

Pfizer Share Price

New

| |

Volume
Price

Quarterly Price

Show Value Show %

Pfizer Quarterly Results

#(Fig in Cr.) Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 593 637 622 573 531 575 540 547 563 589
Other Income 18 24 27 31 33 36 36 75 42 43
Total Income 611 662 649 604 565 611 576 622 605 632
Total Expenditure 401 406 418 391 421 393 387 357 385 399
Operating Profit 210 256 231 213 144 219 188 265 219 232
Interest 4 3 4 3 3 3 3 7 2 2
Depreciation 27 26 26 26 16 15 18 14 15 15
Exceptional Income / Expenses -136 189 0 -20 0 0 8 0 0 0
Profit Before Tax 43 415 201 165 126 201 176 244 203 215
Provision for Tax 11 104 50 35 32 52 46 65 52 57
Profit After Tax 33 311 151 130 94 149 130 179 151 158
Adjustments 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 33 311 151 130 94 149 130 179 151 158
Adjusted Earnings Per Share 7.1 68 32.9 28.3 20.4 32.6 28.4 39.1 32.9 34.6

Pfizer Profit & Loss

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
Net Sales 1112 1853 2012 1966 1969 2082 2152 2239 2611 2425 2193 2239
Other Income 109 72 87 101 114 167 184 81 63 101 181 196
Total Income 1221 1925 2099 2067 2083 2249 2336 2320 2674 2526 2374 2435
Total Expenditure 873 1474 1579 1616 1468 1516 1579 1526 1775 1616 1558 1528
Operating Profit 349 451 520 451 615 733 757 794 899 910 816 904
Interest 1 2 1 2 1 2 11 15 11 13 15 14
Depreciation 8 131 58 63 66 71 103 109 115 106 62 62
Exceptional Income / Expenses 0 -80 10 130 0 0 0 0 0 33 8 8
Profit Before Tax 340 238 470 517 548 660 642 669 773 824 746 838
Provision for Tax 119 138 165 180 188 231 133 171 160 200 195 220
Profit After Tax 221 100 305 337 360 429 509 498 613 624 551 618
Adjustments 0 -31 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 221 70 305 337 360 429 509 498 613 624 551 618
Adjusted Earnings Per Share 74 21.9 66.7 73.6 78.7 93.8 111.3 108.8 133.9 136.4 120.5 135

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -10% -1% 1% 7%
Operating Profit CAGR -10% 1% 2% 9%
PAT CAGR -12% 3% 5% 10%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 28% 2% 4% 10%
ROE Average 16% 20% 19% 16%
ROCE Average 22% 27% 25% 24%

Pfizer Balance Sheet

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Shareholder's Funds 658 1973 2163 2419 2683 3011 3395 2393 2864 3207 3596
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 3 3 0 0 0 0 0 0 0 0
Other Non-Current Liabilities -19 -37 64 62 52 37 136 85 136 38 33
Total Current Liabilities 303 609 658 780 954 892 873 774 853 657 547
Total Liabilities 942 2547 2888 3261 3690 3940 4405 3252 3854 3903 4175
Fixed Assets 20 944 925 867 917 854 942 865 841 749 713
Other Non-Current Assets 237 350 331 343 357 371 415 479 616 629 693
Total Current Assets 686 1252 1614 2033 2403 2702 3013 1873 2361 2493 2738
Total Assets 942 2547 2888 3261 3690 3940 4405 3252 3854 3903 4175

Pfizer Cash Flow

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Opening Cash & Cash Equivalents 1433 308 488 71 68 51 74 1764 151 63 37
Cash Flow from Operating Activities 132 113 345 329 332 98 323 427 667 356 257
Cash Flow from Investing Activities 103 -89 -701 -250 -238 35 1530 -469 -575 -36 54
Cash Flow from Financing Activities -1360 -1 -62 -83 -110 -110 -164 -1571 -181 -346 -235
Net Cash Inflow / Outflow -1125 23 -417 -3 -17 23 1690 -1613 -88 -26 75
Closing Cash & Cash Equivalent 308 488 71 68 51 74 1764 151 63 37 112

Pfizer Ratios

# Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Earnings Per Share (Rs) 74.01 21.93 66.67 73.61 78.7 93.78 111.29 108.77 133.89 136.38 120.51
CEPS(Rs) 76.68 50.59 79.33 87.37 93.18 109.39 133.85 132.68 159.03 159.44 134.12
DPS(Rs) 360 12.5 15 20 20 22.5 330 35 30 70 35
Book NAV/Share(Rs) 220.64 431.28 472.92 528.72 586.49 658.22 742.18 523.07 626.1 701.05 785.91
Core EBITDA Margin(%) 20.54 19.69 20.67 17.15 25.28 27.17 26.62 31.82 30.79 31.6 27.43
EBIT Margin(%) 29.24 12.43 22.53 25.41 27.71 31.79 30.37 30.56 28.86 32.71 32.88
Pre Tax Margin(%) 29.15 12.36 22.47 25.31 27.67 31.7 29.86 29.87 28.46 32.18 32.21
PAT Margin (%) 18.96 5.21 14.57 16.49 18.18 20.61 23.66 22.23 22.56 24.37 23.81
Cash Profit Margin (%) 19.64 12.01 17.33 19.58 21.53 24.04 28.46 27.12 26.79 28.49 26.49
ROA(%) 14.91 5.75 11.22 10.95 10.36 11.25 12.2 13 17.24 16.09 13.65
ROE(%) 18.77 7.63 14.75 14.7 14.11 15.07 15.89 17.19 23.3 20.55 16.21
ROCE(%) 28.96 18.19 22.78 22.62 21.49 23.22 20.38 23.62 29.78 27.56 22.37
Receivable days 49.42 31.59 26.35 22.58 24.43 28.62 29.15 22.89 16.89 20.98 26.74
Inventory Days 49.61 51.1 65.25 61.01 57.05 59.95 69.32 70.57 59.41 61.77 67.09
Payable days 185.5 138.79 175.52 186.15 238.01 250.57 212.28 176.59 114.15 109.36 95.85
PER(x) 17.08 101.69 26.8 25.71 27.77 35.41 36.17 41.57 32.5 25.4 34.8
Price/Book(x) 5.73 5.17 3.78 3.58 3.73 5.04 5.42 8.64 6.95 4.94 5.34
Dividend Yield(%) 28.48 0.56 0.84 1.06 0.92 0.68 8.2 0.77 0.69 2.02 0.83
EV/Net Sales(x) 3.12 5.18 3.55 3.63 4.18 6.38 7.53 8.74 7 5.77 7.82
EV/Core EBITDA(x) 9.94 21.28 13.76 15.82 13.38 18.12 21.4 24.67 20.33 15.37 21.01
Net Sales Growth(%) 6 66.69 8.58 -2.29 0.11 5.74 3.37 4.04 16.64 -7.13 -9.55
EBIT Growth(%) -51.02 -29.69 96.98 9.96 5.76 20.59 -1.23 4.68 14.54 6.88 -9.07
PAT Growth(%) -56.11 -54.57 203.95 10.43 6.92 19.16 18.66 -2.26 23.1 1.86 -11.64
EPS Growth(%) -56.11 -70.36 203.95 10.42 6.92 19.16 18.66 -2.26 23.1 1.86 -11.64
Debt/Equity(x) 0 0 0 0 0 0 0 0 0 0 0
Current Ratio(x) 2.26 2.06 2.45 2.61 2.52 3.03 3.45 2.42 2.77 3.79 5.01
Quick Ratio(x) 1.76 1.42 1.9 2.19 2.21 2.6 2.96 1.87 2.24 3.16 4.22
Interest Cover(x) 310.56 158.68 337.93 264.69 712.57 384.67 59.36 44.45 73.23 62.13 49.35
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0

Pfizer Shareholding Pattern

# Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Promoter 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92
FII 2.55 2.55 2.77 2.8 2.81 2.82 3.03 3.32 3.22 3.54
DII 14.83 14.88 14.93 14.9 14.89 15.01 15.15 15.33 15.84 16.03
Public 18.7 18.65 18.38 18.38 18.38 18.25 17.9 17.42 17.02 16.5
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Debtor days have improved from 109.36 to 95.85days.
  • Company is almost debt free.

Cons

  • Stock is trading at 6.4 times its book value.
  • The company has delivered a poor profit growth of 5% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Pfizer News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....